Table 1.

Patient characteristics. Values in parentheses are percentages.

CharacteristicRA Patients, n = 927
RF+ (available in 852 pts)580 (68.1)
CCP+ (available in 909 pts)700 (77.0)
Female674 (72.7)
Mean age, yrs61.4
Mean disease duration, yrs15.1 [range 3–47]
Erosive disease823 (88.7)
Smoking
  Never387 (41.8)
  Previous352 (38.1)
  Current186 (20.1)
Shared-epitope
  067 (7.2)
  1 copy324 (35.7)
  2 copies525 (57.2)
Treatment
  No DMARD97 (10.5)
  MTX alone214 (23.1)
  Other DMARD*317 (34.2)
  MTX combination229 (24.7)
  Anti-TNF70 (7.5)
  Prednisolone495 (53.3)
  • * Alone or in combination, including sulfasalazine, leflunomide, cyclosporine, gold, and azathioprine.

  • Shared-epitope status available in 916 patients. RF: rheumatoid factor; CCP: cyclic citrullinated peptide; DMARD: disease-modifying antirheumatic drug(s); MTX: methotrexate; TNF: tumor necrosis factor.